A detailed history of Morgan Stanley transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Morgan Stanley holds 340,630 shares of AVXL stock, worth $1.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
340,630
Previous 452,203 24.67%
Holding current value
$1.41 Million
Previous $4.21 Million 58.84%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$4.55 - $6.75 $507,657 - $753,117
-111,573 Reduced 24.67%
340,630 $1.73 Million
Q4 2023

Feb 13, 2024

BUY
$5.04 - $9.95 $906,998 - $1.79 Million
179,960 Added 66.1%
452,203 $4.21 Million
Q3 2023

Nov 15, 2023

SELL
$6.55 - $9.37 $1,120 - $1,602
-171 Reduced 0.06%
272,243 $1.78 Million
Q2 2023

Aug 14, 2023

BUY
$7.66 - $9.5 $83,708 - $103,816
10,928 Added 4.18%
272,414 $2.21 Million
Q1 2023

May 15, 2023

SELL
$8.32 - $11.75 $1.02 Million - $1.43 Million
-121,997 Reduced 31.81%
261,486 $2.24 Million
Q4 2022

Feb 14, 2023

BUY
$7.65 - $14.43 $1.26 Million - $2.39 Million
165,312 Added 75.77%
383,483 $3.55 Million
Q3 2022

Nov 14, 2022

SELL
$8.9 - $12.86 $5.58 Million - $8.06 Million
-626,644 Reduced 74.18%
218,171 $2.25 Million
Q2 2022

Oct 27, 2022

BUY
$7.31 - $12.84 $725,210 - $1.27 Million
99,208 Added 13.31%
844,815 $8.46 Million
Q2 2022

Aug 15, 2022

BUY
$7.31 - $12.84 $725,210 - $1.27 Million
99,208 Added 13.31%
844,815 $8.46 Million
Q1 2022

Oct 27, 2022

SELL
$9.74 - $17.69 $966,285 - $1.75 Million
-99,208 Reduced 11.74%
745,607 $9.18 Million
Q1 2022

May 13, 2022

BUY
$9.74 - $17.69 $3.78 Million - $6.87 Million
388,392 Added 108.73%
745,607 $9.18 Million
Q4 2021

Feb 14, 2022

BUY
$16.88 - $23.31 $1.82 Million - $2.51 Million
107,828 Added 43.24%
357,215 $6.2 Million
Q3 2021

Nov 15, 2021

BUY
$16.82 - $25.75 $4.19 Million - $6.42 Million
249,387 New
249,387 $4.48 Million

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $322M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.